Ligand Pharmaceuticals | LGND - Debt


Ligand Pharmaceuticals reported $451.49M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 54.6B 17M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
Baxter International USD 9.78B 68M Dec/2025
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Enviri Corporation USD 1.44B 3.08M Dec/2024
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.62M 275K Mar/2026
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.34B 7.97B Dec/2025
Pacira USD 367.66M 4.53M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 39.65M 799K Dec/2025